2017_SBRT_Course Book

Trageted Therapy: Described Side effects

Sperduto PW Phase III trial (RTOG 0320) WBRT/SRT

Temozolamid Erlotinib

47% grade ¾ Skin reaction including acne Pneumonia Muscle weakness Myocardial ischemia Brain necrosis

Schulze B

Case reports WBRT

BRAF inhibitor Vermurafenib

Skin toxicity

Kies AP

SRS

Ipilimumab

Symptomatic Radionecrosis

• Targeted therapy in combination with RT can increase side effects • Targeted therapy may have a radiosensitizing effect • Studies have to be performed evaluating side effects